FDA Restrictions on Non-Approved GLP-1 API Use and Marketing   The US Food and Drug Administration (FDA) has announced plans to implement restrictions on the use of glucagon-like peptide-1 (GLP-1) …

Association Between Target Urate Levels and Cardiovascular Outcomes in Gout   Data published in JAMA Internal Medicine indicates that patients with gout who successfully achieve a serum urate level of …

Benefits and Risks of PFO Closure by Causal Likelihood A recent meta-analysis suggests that the benefits of transcatheter PFO closure for secondary stroke prevention rely heavily on the likelihood that …

  A novel cellular rejuvenation therapy, ER-100, has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with human clinical testing, marking what the sponsor describes as …

Brief Report: Prevalence and Economic Burden of Chronic Conditions in the Commercially Insured US Population (2024) Overview A 2024 analysis conducted by FAIR Health presents new data regarding the epidemiology …

  Key takeaways: Using NHANES data from 2017 to 2023, obesity prevalence in the U.S. is 75.2% when excess adiposity cutoffs are used. Among adults with a BMI of less …